$9.73 -0.3 -2.9%
Last Trade - 26/02/21
| Market Cap | ÂŁ1.27bn |
| Enterprise Value | ÂŁ1.27bn |
| Revenue | ÂŁ5.24m |
| Position in Universe | 2280th / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 6.79 | 9.51 | 12.0 | 10.1 | 8.01 | 18.4 | +14.2% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | January 24, 2003 |
| Public Since | August 1, 2018 |
| No. of Shareholders: | 90 |
| No. of Employees: | 97 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 181,680,905 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 9540 Towne Centre Dr Ste 100, SAN DIEGO, 92121-1989, United States |
| Web | https://bionanogenomics.com/ |
| Phone | +1 858 8887600 |
| Contact | () |
| Auditors | Deloitte & Touche LLP |
As of 26/02/21, shares in Bionano Genomics Inc are trading at $9.73, giving the company a market capitalisation of ÂŁ1.27bn. This share price information is delayed by 15 minutes.
Shares in Bionano Genomics Inc are currently trading at $9.73 and the price has moved by 0.924k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bionano Genomics Inc price has moved by 0.690k% over the past year.
Of the analysts with advisory recommendations for Bionano Genomics Inc, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bionano Genomics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Bionano Genomics Inc is scheduled to issue upcoming financial results on the following dates:
Bionano Genomics Inc does not currently pay a dividend.
Bionano Genomics Inc does not currently pay a dividend.
Bionano Genomics Inc does not currently pay a dividend.
To buy shares in Bionano Genomics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Bionano Genomics Inc are currently trading at $9.73, giving the company a market capitalisation of ÂŁ1.27bn.
Here are the trading details for Bionano Genomics Inc:
Based on an overall assessment of its quality, value and momentum, Bionano Genomics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Bionano Genomics Inc are currently priced at $9.73. At that level they are trading at 12.44% discount to the analyst consensus target price of 0.00.
Analysts covering Bionano Genomics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.4 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionano Genomics Inc. Over the past six months, the relative strength of its shares against the market has been 1.33k%. At the current price of $9.73, shares in Bionano Genomics Inc are trading at 0.310k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Bionano Genomics Inc.
Bionano Genomics Inc's management team is headed by:
Here are the top five shareholders of Bionano Genomics Inc based on the size of their shareholding:
